HSBC Holdings
ALXN

HSBC Holdings’s Alexion Pharmaceuticals ALXN Stock Holding History

HSBC Holdings’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-400
Closed -$36K – 2936
2020
Q1 		$36K Buy
+400
New +$39.3K ﹤0.01% 2589
2019
Q4 		– Sell
-36,800
Closed -$3.6M – 3254
2019
Q3 		$3.6M Sell
36,800
-1,800
-5% -$203K 0.01% 1323
2019
Q2 		$5.06M Buy
38,600
+24,000
+164% +$3.09M 0.01% 1140
2019
Q1 		$1.97M Buy
14,600
+8,100
+125% +$1.01M ﹤0.01% 1528
2018
Q4 		$633K Buy
6,500
+2,800
+76% +$331K ﹤0.01% 2009
2018
Q3 		$514K Sell
3,700
-9,700
-72% -$1.22M ﹤0.01% 2014
2018
Q2 		$1.66M Buy
13,400
+9,700
+262% +$1.13M ﹤0.01% 1569
2018
Q1 		$412K Buy
+3,700
New +$442K ﹤0.01% 2039
2017
Q4 		– Sell
-3,700
Closed -$519K – 2461
2017
Q3 		$519K Buy
+3,700
New +$503K ﹤0.01% 1714
2015
Q3 		– Sell
-96,832
Closed -$17.5M – 2225
2015
Q2 		$17.5M Buy
+96,832
New +$16.7M 0.04% 455
2015
Q1 		– Sell
-700
Closed -$130K – 2146
2014
Q4 		$130K Buy
+700
New +$130K ﹤0.01% 1728

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

HSBC Holdings's ALXN Position: Q3 2021 in Review

HSBC Holdings sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 454,149 shares — an estimated $83.5M sold.

HSBC Holdings first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $97.6M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • HSBC Holdings reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • HSBC Holdings sold 454,149 Alexion Pharmaceuticals shares in Q3 2021, an estimated $83.5M.
  • HSBC Holdings first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • HSBC Holdings's Alexion Pharmaceuticals position peaked at $97.6M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on HSBC Holdings's 13F filing for Q3 2021, filed 12 Nov 2021.